Применение ингибиторов ангиотензинпревращающего фермента в лечении артериальной гипертонии

1. Шальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Рос. кардиол. журн. 2006; 4: 45–50.
2. Ferreira SH. A bradikinin-potentiating factor (BPF) present in the venom of Bothrops jararaca. Br J Pharmacol Chemother 1965; 24: 163–9.
3. Yang HY, Erdos EG, Levin E. A dipeptidyl carboxypeptidase that converts angiotensin-1 and inactivates bradykinin. Biochim Biophis Acta 1970; 214: 374–6.
4. Cushman DW, Ondetti MA. Personal and historical perspectives: History of the design of captopril and related inhibitors of angiotensin converting enzyme. Hyperetension 1991; 17: 589–92.
5. Patchett AA, Harris E, Tristram EW et al. A new class of angiotensin-converting enzyme inhibitors. Nature 1980; 288: 280–3.
6. Opie LH. Angiotensin converting enzyme inhibitors. Authors Publishing House, New York, 1992.
7. Johnston CI. Angiotensin-converting enzyme inhibitors. In: Robertson JI, Nicholson MG. (ed.) The renin-angiotensin system. London, New York: Gower Medical Publishing 1993; 87.1–87.15.
8. Murdoch D, Tavish D. Fosinopril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in essential hypertension. Drugs 1992; 43: 123–40.
9. Wagstaff AJ, Davis R, McTavish D. Fosinopril: a reapprasal of its pharmacological efficacy in essential hypertension. Drugs 1996; 51: 777–91.
10. Lund-Johansen P, Omvik P. Long-term haemodynamic effects of enalapril (alone and in combination with hydrochlorothiazide) at rest and during exercise in essential hypertension. J Hypertens 1984; 2: S49–50.
11. Ibsen H, Egan B, Osterzeil K, Vander A, Julius S. Reflex-hemodynamic adjustments and baroreflex sensitivity during converting enzyme inhibition with MK-421 in normal humans. Hypertension 1983; 5 (suppl. I): I-184–I-9.
12. Dunn GF, Oigman W, Ventura HO et al. Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. Am J Cardiol 1984; 53: 105–8.
13. Simon AC, Levenson JA, Bouthier J et al. Effects of acute and chronic angiotensin enzyme inhibition on large arteries in human hypertension. J Cardiovasc Pharmacol 1985; 7: S45–51.
14. Cody RJ, Tarazi RC, Bravo EL, Fouad FM. Haemodynamics of orallyactive converting enzyme inhibitor (SQ 14225) in hypertensive patients. Clin Sci Mol Med 1978; 55: 453–9.
15. Fouad FM, Tarazi RC, Bravo EL. Cardiac and haemodynamic effects of enalapril. J Hypertens 1983; 1 (suppl. 1): 135–42.
16. Fagard R, Amery A, Reybrouck T et al. Acute and chronic systemic and hemodynamic effects of angiotensin converting enzyme inhibition with captopril in hypertensive patients. Am J Cardiol 1980; 46: 295–300.
17. Tarazi RC, Bravo EL, Fouad FM et al. Hemodynamic and volume changes associated with captopril. Hypertension 1980; 2: 576–85.
18. Muiesan G, Alicandri CL, Agabiti-Rosei E et al. Angiotensin-converting enzyme inhibition, catecholamines and hemodynamics in essential hypertension. Am J Cardiol 1982; 49: 1420–4.
19. Horning B, Landmesser U, Kohler C et al. Comparative effects of ace inhibition and angiotensin II type receptor antagonism on bioavailability of nitric oxide in patients with coronary heart disease: role of superoxide dismutase. Circulation 2001; 103: 799–805.
20. Horning B, Arakawa N, Drexler H. Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure. Eur Heart J 1998; 19 (Suppl. G): G48–53.
21. Brunner HR, Gavras H, Waeber B et al. Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. Ann Intern Med 1979; 90: 19–23.
22. Gavras H, Brunner HR, Turini GA et al. Antihypertensive effect of the oral angiotensin converting enzyme inhibitor SQ 14225 in man. N Engl J Med 1978; 298: 991–5.
23. Vander AJ, Geelhoed GW. Inhibition of renin secretion by angiotensin II. Proc Soc Exp Biol Med 1965; 120: 399–403.
24. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. Am J Hypertens 1992; 5: 95–110.
25. Brilla CG, Janicki JS, Weber KT. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation 1991; 83: 1771–9.
26. Weber JR. Left ventricular hypertrophy: its prevalence, etiology and significance. Clin Cardiol 1991; 14 (Suppl. III): 13–7.
27. Peng H, Carretero O, Vuljaj N et al. Angiotensin-Converting Enzyme Inhibitors: A New Mechanism of Action. Circulation 2005; 112 (16): 2436–45.
28. Schlueter WA, Battle DC. Renal effects of antihypertensve drugs. Drugs 1989; 37: 900–25.
29. Hall J.E. Intrarenal actions of converting enzyme inhibitors. Am J Hypertns 1989; 2: 875–84.
30. Nishijama K, Igari T, Nanda S, Ishii M. Long-term effects of delapril on renal function annd urinary excretion of kallikrein, prostaglandin E2, and thromboxan B2 in hypertensive patients. Am J Hypertens 1991; 4: 52S–3S.
31. Brichard S, Lambert A.E. Perindopril safety and tolerance in at risk patients. Drugs 1990; 39 (Suppl. 1): 64–70.
32. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. J Clin Invest 1995; 95: 995–1001.
33. Ridker PM, Gaboury CL, Conlin PR et al. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Circulation 1993; 87: 1969–73.
34. Emeis JJ, Tranquille N. On the role of bradykinin in secretion from vascular endothelial cells. Agents Actions 1992; 38: 285–91.
35. Brown NJ, Nadeau J, Vaughan DE. Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb Haemost 1997; 77: 522–5.
36. Pitt B. Potential role of angiotensin converting enzyme inhibitors in the treatment of atherosclerosis. Eur Heart J 1995; 16: 49–54.
37. Schoelkens BA, Landgraf W. ACE inhibition and atherosclerosis. Can J Physiol Pharm 2002; 80: 354–9.
38. Dagenais GR, Pogue J, Fox K et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006; 368 (9535): 581–8.
39. Zanchetti A, Crepaldi G, Bond G et al. Different Effects of Antihypertensive Regimens Based on Fosinopril or Hydrochlorothiazide With or Without Lipid Lowering by Pravastatin on Progreesion of Asymptomatic Carotid Atherosclerosis. Stroke 2004; 35:
40. Zhuo J, Moeller I, Jenkins T et al. Mapping tissue angiotensin-converting enzyme and angiotensin AT1, AT2 and AT4 receptors. J Hypertens 1998; 16: 2027–37.
41. Opie LH. Angiotensin Converting Enzyme Inhibitors. The Advance Continues. Third Edition. Authors Publishing House. New York. 1999.
42. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–53.
43. Bosch J, Yusuf S, Pogue J et al. HOPE Investigators. Use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002; 324: 699–702.
44. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41.
45. Hansson L, Lindholm L, Ekbom T et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial on Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751–6.
46. Hansson L, Lindholm L, Niskanen L et al. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999; 353: 611–6.
47. Wing LM, Reid CM, Ryan P et al. A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the erderly. N Engl J Med 2003; 348: 583–92.
48. Рекомендации ВНОК "Профилактика, диагностика и лечение артериальной гипертензии", 2-й пересмотр. М., 2004.
49. Kang PM, Landau AJ, Eberhardt RT, Frishman WH. Angiotensin II receptor antagonists: a new approach to blockade of the renin-angiotensin system Am Heart J 1994; 127: 1388–401.
50. Ferner RE, Simpson JM, Rawlins MD. Effects of intradermal bradykininn after inhibition of angiotensin converting enzyme. Br Med J 1987; 294: 1119–20.

А.С.Галявич

Казанский государственный медицинский университет